Loading company…
Sparx develops antibody therapies, antibody drug conjugates and cell therapies for cancer treatment.
Sparx is a development-stage biopharmaceutical company working on immune anti-tumor therapies, including multi-specific antibodies and CAR-T cell therapies. Established in 2021 and based in Yangzhou, China, it has identified 6 IND-ready drug candidates and plans to build production facilities in Yangzhou.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in